During coevolution with the host, HIV-1 developed the ability to hijack the cellular ubiquitin/proteasome degradation pathway to counteract the antiviral activity of APOBEC3G (A3G), a host cytidine deaminase that can block HIV-1 replication. Abrogation of A3G function involves the HIV-1 Vif protein, which binds A3G and serves as an adapter molecule to recruit A3G to a Cullin5-based E3 ubiquitin ligase complex. Structure-guided mutagenesis of A3G focused on the 14 most surface-exposed Lys residues allowed us to identify four Lys residues (Lys-297, 301, 303, and 334) that are required for Vif-mediated A3G ubiquitination and degradation.
H
uman APOBEC3G (hA3G), is a host cytidine deaminase that has two homologous Zn cluster (H/C)XE(X) 23ϳ28 CXXCcontaining domains [reviewed in (1, 2) ]. Sheehy et al. (3) identified hA3G as the cellular factor that blocks HIV-1 replication in certain T cells (e.g., H9 or primary T-cell lymphocytes) in the absence of the viral protein Vif. Cellular expression of A3G results in its incorporation into vif-deficient HIV-1 particles, whereas the presence of A3G in wild-type (WT) virions is dramatically reduced by Vif-induced degradation via the ubiquitination-proteasome pathway before virion assembly and release (4) (5) (6) (7) (8) (9) . There is also evidence for other degradationindependent mechanisms (10, 11 and references therein).
In the absence of Vif, virion-encapsidated A3G causes extensive C-to-U mutations in synthesized minus-strand viral DNA and also physically blocks reverse transcription, rendering the virus noninfectious [(12-14) and reviewed in (11) ]. Thus, given Vif's critical role in eliminating A3G function, it may be viewed as one of the most attractive pharmacologic targets for an anti-HIV drug aimed at restoring the activity of the intrinsic antiviral factor A3G in the context of HIV-1 infection. Indeed, such efforts have already begun. A recent report describes the small molecule inhibitor (RN-18) that increases cellular levels of A3G and incorporation of A3G into virions in a Vif-dependent manner (15) .
Ubiquitination is catalyzed by a complex cascade system consisting of the ubiquitin (Ub)-activating (E1), Ub-conjugating (E2), and Ub-ligating (E3) enzymes (16, 17) . Among these enzymes, the E3 class represents a diverse family of protein complexes, responsible for the selection of the target proteins. In particular, the Cullin-based E3 enzymes belong to the family of RING E3 Ub ligases that contain three main components: a Cullin (Cul1, 2, 3, 4a, 4b, 5, and 7), an adaptor, and a substrate receptor (18) . In the Vif-A3G system, these proteins are Cul5, elongin B/C (EloB/C), and Vif, respectively. Cullin functions as a molecular scaffold on which the adaptor protein and receptor assemble to bring a specific substrate in close proximity to the E2 Ub-conjugating enzyme. The substrate receptor determines the specificity of the protein to be degraded and binds to Cullin through the adaptor protein. The E2-conjugating enzyme transfers multiple Ub molecules to the substrate, targeting it for degradation by the proteasome.
In general, the first Ub is typically conjugated to an -amino group of an internal Lys in the substrate (in this case, A3G). HIV-1 Vif, serving as the substrate receptor, facilitates ubiquitination of A3G by simultaneously binding to the Cul5-EloB/ EloC-Rbx-E2 complex, thereby mimicking the function of cellular suppressor of cytokine signaling (SOCS) box proteins (9, (19) (20) (21) . The SOCS box-like motif of Vif is highly conserved among primate lentiviruses and contains a BC box, as well as a Cullin box. The BC box motif creates a hydrophobic interface for binding to EloC. The Cullin box has a specific site for binding to Cul5, which involves an interaction between the highly conserved HCCH zinc-binding motif in Vif and the N-terminal domain (NTD) of Cul5 (22, 23) .
Interestingly, it has been reported that Vif contains three sequence motifs for binding to A3G: 12 (24) (25) (26) . The region in A3G responsible for binding to HIV-1 Vif was initially identified by comparative studies of the species specificity of A3G degradation by Vif. Thus, a single amino acid difference in hA3G, Asp at position 128 versus Lys in the A3G of African green monkeys (A3G agm ), determines species specificity by influencing Vif-A3G binding (27) (28) (29) (30) . Furthermore, extensive site-directed mutagenesis revealed that the 128 DPD 130 motif of A3G, located near the first Zn cluster, is crucial for direct binding to HIV-1 Vif. It is of interest that this motif is just downstream of residues 124 YYFW 127 , which are involved in A3G's ability to bind nucleic acids (31) .
The information available thus far concerning the interaction between Vif and A3G in the Ub ligase complex suggests that there may be a specific mechanism for Ub conjugation of the A3G protein. Yet, despite our knowledge that the participants interact with each other in the EloB/C-Cul5-Vif-A3G complex, the details of how the complex dictates A3G polyubiquitination and subsequent degradation remain unclear. In part, this is due to the lack of complete structural information about the A3G and Vif proteins and the complex they form. Our approach to this problem was to construct a structural model of hA3G for testing which Lys residues may serve as targets for ubiquitination. Based on the structural model we selected 14 surfaceexposed Lys and established that only four of these residues (Lys-297, 301, 303, and 334) in the C-terminal domain (CTD) are essential for Vif-induced degradation of A3G. In addition, we demonstrated that a ''super'' A3G (S-A3G) with all of these four residues mutated to Arg was resistant to degradation by Vif and was able to block replication of WT HIV-1. Taken together, our results provide insights into the determinants governing Vifmediated A3G inactivation and should stimulate and aid efforts to develop antiviral strategies that focus on disruption of the Vif-A3G interaction.
Results
The A3G Model Shows 14 Lys Residues with Substantially Exposed -Amino Groups. The goal of the present study was to identify Lys residues in hA3G that become ubiquitinated in a Vif-dependent manner, resulting in subsequent degradation by the proteasome pathway. In general, during polyubiquitination, the first ubiquitin is typically conjugated to an -amino group of an exposed Lys within the target protein (16) . For hA3G, the amino acid sequence contains 20 Lys residues (Fig. S1 ), 14 of which are completely accessible on the surface in a model structure (Fig.  S2) . Our model structure was based on the X-ray structures of the A3G catalytic domain (32) and the related homodimeric A2 protein (33) and was generated to guide our selection of the most solvent accessible Lys residues. Homology models for the NTD and CTD were generated using the program Modeller (http:// salilab.org/modeller) (34) and the relative positioning of the domains in the A3G model was based on the arrangement of the monomeric A2 proteins in the homodimer. The most exposed Lys residues were found at positions 63, 76, 79, 99, 113, 141, 180, 249, 270, 297, 301, 303, 334, and 344, and are highlighted in blue in the amino acid sequence of hA3G (Fig. S1 ). In the following discussion they are designated as K1-14, respectively.
Arg Substitutions for Lys-297, 301, 303, and 334 Render A3G Resistant to Vif-Mediated Degradation. In an effort to identify which Lys residue(s) may be responsible for A3G ubiquitination, Arg substitutions were made at the selected 14 positions in A3G and mutants were assayed for intracellular degradation. In particular, we tested whether HIV-1 Vif enhanced degradation (''Vif sensitivity'') of A3G was affected. Initially, 14 point mutants were constructed and each mutant remained Vif-sensitive (Fig.  S3 ). This suggested that most likely, more than one residue might be required for conversion to a Vif-resistant phenotype.
To address this question (i.e., whether several Lys residues may be involved), a series of mutants was constructed, each containing changes for a number of Lys residues (Fig. 1 ). Five mutants, K (1-9)R, K(1-4)R, K (5-9)R, K(8-14)R, and K(10-14)R, with Arg substitutions at positions K1-9, 1-4, 5-9, 8-14, and 10-14, respectively, were generated ( Fig. 1 A) and the presence of A3G was probed by Western blot analysis (see legend to Fig. 1 ). As expected, WT A3G was not detectable when co-expressed with HIV-1 Vif (Vif-sensitive), while the level of the D128K A3G mutant protein that lacks the ability to bind HIV-1 Vif (27-30) was unchanged in the presence of Vif (Vif-resistant) (Fig. 1B) . The K (1-9)R, K(1-4)R, and K(5-9)R mutants were sensitive to Vif, i.e., they behaved like WT A3G in this assay. In contrast, protein levels of the K(8-14)R and K(10-14)R mutants were unaffected (i.e., Vif-resistant) (Fig.  1B) . This suggested that all five Lys residues from 10 through 14, or a subset thereof, were critical for mediation of Vif-dependent ubiquitination. To resolve this point, a second series of A3G mutants with different permutations of the four substitutions in residues 10-14 was evaluated. Only K(10, 11, 12, 13)R was completely Vif-resistant, although K(10, 12, 13, 14)R and K(10, 11, 13, 14)R were partially resistant (Fig. 1C) . This result demonstrated that Lys residues 10, 11, 12, and 13 are critical determinants of HIV-1 Vif-dependent ubiquitination of A3G, since Arg substitutions in these residues abolished Vif sensitivity, Furthermore, three substitutions within the four residues conferred varying degrees of A3G sensitivity to Vif. To corroborate these conclusions, we compared the amounts of A3G WT and K(10-13)R proteins for varying ratios of pcDNA-HVif/pcDNA 3.1 (-). While significant WT A3G protein was present at low Vif concentrations (Fig. 1D , lanes 4-6), no difference in protein amounts was observed for the K(10-13)R mutant at every concentration of Vif that was tested (Fig. 1D, lanes 8-13) . Thus, K(10-13)R is resistant to Vif-mediated degradation and we will refer to mutant K(10-13)R as ''super'' A3G (S-A3G) below. We also observed S-A3G Vif resistance in nonpermissive SupT1 T-cell lymphocytes (Fig. S4) .
The Additional C-Terminal Tag of A3G Can Mediate UbiquitinationInduced Proteasomal Degradation. In an initial phase of this study, quite unexpectedly, we found that an A3G mutant with all 14 Lys residues changed to Arg and also having a C-terminal tag was sensitive to Vif-dependent degradation. This surprising result prompted us to test whether the two Lys residues in the C-terminal A3G tag (MycHIS) might become ubiquitinated. We therefore constructed A3G expression plasmids with a Lys-free MycHIS tag and compared the Vif sensitivity of this construct with that of untagged and conventional MycHIS tagged WT and S-A3G plasmids. As clearly seen in Fig. 2 , S-A3G protein levels were similar in the absence or presence of HIV-1 Vif. In contrast, the addition of the C-terminal MycHIS tag rendered S-A3G (S) susceptible to the presence of Vif, exhibiting behavior very similar to that of WT A3G. This was reversed when the Lys-free MycHIS version of S-A3G was used. In this case, complete resistance to Vif-dependent A3G degradation was noted. These findings demonstrated that the two Lys in the C-terminal tag can serve as ubiquitination sites. Note that identical protein levels were detected irrespective of the type of antibodies (anti-A3G, anti-Myc or anti-HIS antibodies) used for detection (Fig. 2) .
The dependence of A3G polyubiquitination on Vif was investigated by expressing the Lys-free MycHIS tagged A3G in 293T cells. The results showed that no polyubiquitinated S-A3G was detectable, whereas Vif-dependent WT A3G polyubiquitination was clearly observed (Fig. S5) . This demonstrates that S-A3G's resistance to Vif-dependent degradation was due to its inability to be polyubiquitinated, presumably as a consequence of the four Lys mutations.
S-A3G Displays Normal Vif Binding. Abrogation of Vif binding by A3G could also confer resistance to Vif-dependent degradation, as was observed for the D128K mutant (27) (28) (29) (30) . It therefore seemed prudent to determine whether Arg substitutions at A3G residues 297, 301, 303, and 334 would in any way interfere with A3G's ability to bind Vif. We expressed WT and S-A3G (bearing the Lys-free MycHIS tag) in the presence of the proteasome inhibitor MG132 (2 M), with or without Vif. Intracellular A3G-Vif complexes were pulled down with Talon beads via the HIS portion of A3G's C-terminal tag and the complexes were detected by either anti-A3G or anti-Vif antibodies (Fig. 3A) . Coprecipitated complexes of WT or S-A3G contained very similar amounts of Vif, indicating that no impairment of Vif binding resulted from the mutations in S-A3G. As expected, no Vif was detected in the controls.
S-A3G Inhibits HIV-1 Infection. To assess the implications of S-A3G's resistance toward Vif-dependent proteasomal degradation, we tested whether S-A3G exhibited any antiviral activity against HIV-1. To this end, we compared the infectivity of WT and vif-deficient HIV-1 in the presence of WT or S-A3G in a single-round replication assay. Since A3G expression levels and the extent of the antiviral effect vary for different virus-producer Where appropriate, the amounts of DNA added for each of the expression plasmids were adjusted with empty vector pcDNA 3.1 (-) to a total of 2 g. Infectivity values are given relative to the values for 0 g of the expression plasmids and were set at 100%. (C) Analysis of intracellular expression (Cell) and incorporation of WT and S-A3G into virions (Virus) by Western blot. Virions were produced by transfection of pNL4 -3 WT/pNL4 -3vif(-) plus either A3G WT, S-A3G expression plasmid or pcDNA 3.1(-) (shown as ''no''). The ratios of pNL4 -3 WT to pNL4 -3vif(-) were as follows. 1:0 (lanes 1, 2 and 8), 1:1 (lanes 3 and 9), 1:3 (lanes 4 and 10), 1:7 (lanes 5 and 11), 1:79 (lanes 6 and 12), and 1:0 (lanes 7 and 13). The intracellular levels of ␤-tubulin and Vif and the CA level in virions were detected by anti-␤-tubulin, anti-Vif, and anti-CA antibodies, respectively. cell lines (35, 36) , we measured infectivity in this assay as a function of the amount of transfected DNA. Comparing infectivity for a given amount of A3G to infectivity in the absence of A3G was termed ''relative infectivity.'' Interestingly, using 0.1 and 2.0 g WT A3G DNA for transfection reduced the infectivity of vif-deficient HIV-1 to 24 and 0.8%, respectively, while only marginally affecting the infectivity of WT HIV-1 (95 and 71% with 0.1 and 2.0 g, respectively) (Fig. 3B) . In contrast, S-A3G suppressed the infectivity of vif-deficient as well as WT HIV-1 significantly, consistent with its Vif-resistant phenotype. Furthermore, we could show that a deaminase-deficient version (E259Q) of S-A3G had less antiviral activity than S-A3G against WT and vif-deficient HIV-1 (Fig. S6) . Note, too, that in the absence of Vif, E259Q mutants derived from WT and S-A3G had the same levels of inhibitory activity (Fig. S6B) . Collectively these results suggest that the catalytic activity and the antiviral function of S-A3G and WT A3G are equivalent.
To determine whether the inhibitory effect of S-A3G on WT HIV-1 infectivity is correlated with a defect in efficient incorporation of S-A3G into virus particles, we analyzed the amounts of intracellular A3G and A3G packaged into virions as a function of Vif expression (i.e., by transfecting different ratios of pNL4-3/pNL4-3 vif(-) together with either WT A3G or S-A3G) (Fig.  3C ). As Vif expression was increased, the steady state levels of intracellular WT A3G were decreased (Cell, lanes 2-6), while the levels of S-A3G protein were not affected (Cell, lanes [8] [9] [10] [11] [12] . Concomitant with the decrease in protein levels of intracellular WT A3G, its incorporation into virions was also reduced (Virus, lanes 2-6), while under identical experimental conditions, S-A3G packaging was not significantly affected (Virus, lanes [8] [9] [10] [11] [12] ). These findings demonstrate that S-A3G incorporation into HIV-1 virions is independent of Vif. Therefore, efficient packaging of S-A3G into HIV-1 virus particles occurs and allows S-A3G to exert its inhibitory effect on viral infectivity.
The Critical Residues Involved in Vif-Mediated A3G Degradation
Cluster at the C Terminus of the Protein. Identification of the Lys residues crucial for Vif-mediated A3G degradation in conjunction with the molecular model for the protein allowed us to determine their location. All 14 candidate Lys are displayed on the model in Fig. 4 . As can be readily observed, the critical residues involved in ubiquitination and proteasomal degradation of A3G (i.e., Lys 297, 301, 303, and 334) cluster in one region of the molecule. This area is located at the opposite end of the known interaction region with Vif (D128, P129, and D130) (31) . Interestingly, the critical Lys residues are also close to the C terminus of the polypeptide chain, with K334 located within approximately 13Å. Note that this model also positions the Lys residues of the MycHIS tag in the same general area (Fig. 4A,  green) , possibly explaining our findings regarding Vif-sensitivity of MycHIS tagged S-A3G.
Discussion
The goal of the present study was to provide information about HIV-1 Vif-induced degradation of hA3G, in particular the initial polyubiquitination step (i.e., conjugation of Ub to Lys residues in A3G). Using structure-based mutagenesis as our experimental approach, we identified four Lys residues at positions 297, 301, 303, and 334 in the CTD of A3G that are critical for Vifdependent degradation. Mutation of these residues to Arg generated a protein, S-A3G, which is resistant to intracellular degradation mediated by HIV-1 Vif. Importantly, the interaction between WT A3G and S-A3G with Vif is very similar and S-A3G is incorporated into WT and vif-deficient viral particles to the same extent. In addition, S-A3G dramatically reduces the infectivity of both WT and vif-deficient HIV-1 (Fig. 3) .
To evaluate ubiquitination of A3G at the structural level, we constructed a model of full-length A3G (Fig. S2) based on the crystal structures of the A3G catalytic domain (32) and A2 (33) , yielding a domain arrangement of N-and C-terminal domains similar to the individual subunits in homodimeric A2. The structures of the individual domains are very similar to those of other cytidine deaminases and are characterized by a fivestranded mixed beta sheet and five alpha helices. The current CTD of our model is not substantially different from the CTD structures that were recently determined by X-ray crystallography and NMR (32, (37) (38) (39) . Since we created and used our homology model to guide the current mutagenesis, several other models of A3G have become available (40, 41) . Most exhibit a domain disposition similar to the one shown here. Very recently a divergent model has been proposed in which the domains are rotated and the ß-sheet arrangement seen in A2 is not retained (39) . Although in this model the details in location of Lys residues will vary, the fact that the Vif interaction site and the critical C-terminal Lys cluster are found at opposite ends of the molecule is still valid.
Even though mutation of these four Lys to Arg residues is the minimum requirement for blocking ubiquitination of A3G, it is of interest to evaluate whether any of these four residues is more favored than others as targets for modification. Both A3G mutants K(10, -, 12, 13, 14)R and K(10, 11, -, 13, 14)R are only partially resistant to ubiquitination compared with A3G K(10, 11, 12, 13, -)R, the molecule termed S-A3G (Fig. 1C) . This suggests that Lys-301 and Lys-303 (K11 and K12, respectively) are used to a lesser extent than Lys-297 and Lys-334 (K10 and K13, respectively) for ubiquitination. Indeed, it is entirely possible that Lys-297 and Lys-334 represent the two required Lys for Vif-induced A3G degradation and that the two Lys that follow Lys 297, Lys 301 one turn further down the helix and Lys-303 in the following helix, may be able to partially substitute as targets ( Fig. S1) . Interestingly, Lys-297 and 334, the most sensitive of the four residues, are highly conserved among primate A3Gs compared with Lys-301 and 303 (Fig. S7) .
Surprisingly, in a mutagenesis study similar to the work reported here, Dang et al. found that mutation of all 20 Lys residues in A3G to Arg had no effect on Vif-induced degradation of A3G (42) . In an additional test of our model, we also mutated all 20 Lys in A3G (A3G 20K/R) and assayed Vif sensitivity, as well as antiviral activity. Our data showed that like K(1-14)R (the mutant in which all surface-exposed Lys were changed to Arg), A3G 20K/R, 19K/R, and 17K/R were also resistant to Vif-dependent degradation (Fig. S8A) . Moreover, the results indicated that A3G 20K/R, like S-A3G, can suppress virus infectivity even in the presence of Vif (Fig. S8B) . These findings differ from the report by Dang et al. (42) , but the reasons for the apparent discrepancy between our results and those published previously are not clear.
In contrast to the residues that are involved in ubiquitination of A3G, amino acids implicated in Vif binding are located in the NTD (43) within the 128 DPD 130 motif (31, 43) that is embedded in the 126 FWDPDYQ 132 (25) sequence in a loop preceding helix 4, which protrudes out from the overall structure (Fig. S2) . Significantly, this motif resides on a site opposite to the location of residues involved in ubiquitination in the overall structure (Fig. 4A) . Consistent with the model, Vif binding by WT A3G and S-A3G are similar, as evidenced by the coimmunoprecipitation results (Fig. 3A) .
In the absence of an experimentally determined threedimensional structure of HIV-1 Vif, predictions about the configuration of the A3G-Vif-ElonginB/C-Cullin-5 E3 Ub ligase complex can only be speculative. Based on the Skp1-Cul1-Rbx1-F box Skp2 (SCF) structure (44) we propose the following scenario for positioning A3G in the complex (Fig. 4B) . It is generally accepted that the cullins provide a rigid scaffold for positioning donor and acceptor proteins in the ubiquitination reaction catalyzed by E3. Indeed, mutants in Cul 1 that were designed to eliminate the integrity of the scaffold are deficient in Ub catalysis (44) . Moreover, studies on the SCF complex suggested that positioning can explain Lys specificity, i.e., which Lys are the targets for ubiquitination. For example, IkB and SnoN, which are among the few ubiquitinated proteins that have been characterized in detail, are ubiquitinated at specific Lys residues by the SCF and SCF-like complexes consistent with their structural positioning (45, 46) . Similarly, our data suggest that Vif-dependent ubiquitination of A3G in the context of a Cul5-based complex specifically occurs on a site that is located at the end of the protein opposite to the region involved in Vif binding. Thus, spatial constraints imposed by the E3 Ub ligase complex involving Cul5 may be an important determinant for Vif-dependent A3G ubiquitination. It is of interest that HIV-2 and SIV mac Vif proteins target the same Lys residues in hA3G as HIV-1 Vif (Fig. S9) . Thus, all three Vif proteins might form complexes with similar structural constraints.
Based on the SCF structural data (45, 46) , it seems reasonable to assume that the distance between the E2 active-site Cys and the Ub-modification site on the substrate also plays an important role in activity (44, 47) . The average distance in the SCF complexes is approximately 60 Å (44, 47) . In the present A3G model, the distance between the 128 DPD 130 cluster and the critical Lys residues ranges from 45Å to 60Å, very similar to the distance between the E2 active-site Cys and the substratebinding site within the Cul 5-EloB/C-Vif-Rbx2-E2 complex. Interestingly, in a recent study by Russell et al. on A3F, the Vif binding region was identified as amino acids 283 to 300 (25) . Reference to the A3G structural model suggests that the A3F Vif-binding site corresponds to the A3G ubiquitination region where Lys-297, 301, and 303 are located.
In summary, using model-guided mutagenesis, we have identified four Lys residues in the CTD of A3G that are required for Vif-mediated polyubiquitination and degradation. We show that substitution of four critical Lys to Arg (S-A3G) confers Vifresistance to A3G and restores A3G's antiviral activity irrespective of Vif. At present, since no polymorphisms at these residues have been reported for hA3G, the natural appearance of A3G variants such as S-A3G is highly unlikely. However, identification of a specific target molecule that removes Vif's inhibitory effect on A3G could advance efforts to develop anti-HIV-1 drugs. Similarly, efforts to design specific screening assays for anti-Vif compounds in vitro will benefit from further characterization of the Vif-A3G interplay with respect to proteasomal degradation.
Materials and Methods
Construction of A3G Structure Model. A homology model of A3G was created based on sequence alignment (automated and adjusted by hand) and subsequent use of the program Modeller (http://salilab.org/modeller) (34) with the crystal structure of the A3G catalytic domain (32) (PDB accession code 3E1U) as the template for the individual NTD and CTD domains. The relative positioning of the NTD and CTD of the template was carried out by superimposing the separated domains onto the crystal structure of A2 (33) (PDB accession code 2NYT). The choice of interface between the two halves of A3G was guided by energy considerations of the final models. The current model in which the beta strands form the dimer interface is energetically more favorable than an alternative one with an alpha helical domain interface.
Plasmids and Antibodies. The plasmids and antibodies used in this work are described in the SI Text.
Coimmunoprecipitation Assays. To assess Vif-A3G interaction in vivo, a assay was performed. Briefly, 293T cells were cotransfected with an A3G plasmid having a Lys-free MycHIS tag and with pcDNA-HVif. Thirty-six hours post transfection, the cells were incubated for 12 h with 2 M MG132, a proteasome inhibitor (Sigma). The presence of MG132 makes it possible to detect WT A3G binding to Vif, since the usual proteasomal degradation is blocked. The cells were harvested and then lysed in lysis buffer (150 mM NaCl, 1 mM EDTA, PBS, 1% Triton X-100, 10 g/mL of RNase A) plus a protease inhibitor mixture (Sigma). TALON beads (Clontech), which bind His, were used to pull down tagged A3G and were washed with lysis buffer. The complex was analyzed by Western blot with anti-A3G rabbit serum or anti-Vif antibody.
Assays for Vif-Dependent Degradation of A3G, Infectivity in LuSIV Cells and Incorporation of A3G Into Virions. These experiments were performed as reported previously (48) .
